Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963679 | 1.00 | TSHR (0.44) | TSHREPHX2CHRM2CHRM4CHRM1 | |
| SCHEMBL24119083 | 1.00 | TSHR (0.44) | TSHREPHX2CHRM2CHRM4CHRM1 | |
| SCHEMBL6050318 | 0.83 | — | — | |
| SCHEMBL28924416 | 0.82 | TSHR (0.35) | TSHREPHX2 | |
| SCHEMBL756556 | 0.80 | TSHR (0.38) | TSHR | |
| SCHEMBL25293694 | 0.79 | LMNA (0.32) | CHRM2CHRM4CHRM1BLMLMNA | |
| SCHEMBL30175181 | 0.78 | LMNA (0.31) | BLMLMNA | |
| SCHEMBL6559706 | 0.77 | TSHR (0.50) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL873507 | 0.77 | TSHR (0.50) | TSHRLMNASMN1; SMN2 | |
| SCHEMBL11170830 | 0.77 | TSHR (0.50) | TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031106-B2 | Use of 1-ethyl-4,4-dimethyl-cyclohexane derivatives as fragrances | SYMRISE AG (DE) | 2024-07-09 | — | — | US | disclosed |
| US-20210395640-A1 | USE OF 1-ETHYL-4,4-DIMETHYL-CYCLOHEXANE DERIVATIVES AS FRAGRANCES | SYMRISE AG (DE) | 2021-12-23 | — | — | US | disclosed |
| WO-2020098901-A1 | USE OF 1-ETHYL-4,4-DIMETHYL-CYCLOHEXANE DERIVATIVES AS FRAGRANCES | SYMRISE AG (DE) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12031106-B2 | Use of 1-ethyl-4,4-dimethyl-cyclohexane derivatives as fragrances | ACMSD, ETV1, HTR1D | TSHR 4578/4885EPHX2 114/4885CHRM2 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.